News
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...
JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical ...
New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...
The initiative will provide practical insights into understanding of obesity pathophysiology and its management.
Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
API and Eli Lilly launch nationwide CME programme to strengthen obesity care among indian physicians
The Obesity Gurukul initiative will train over 20,000 healthcare professionals across India through a hybrid education model ...
Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...
Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program
Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...
This segment is sponsored by Eli Lilly and Company.Social media is flooded with advertisments for popular obestiy medications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results